Advertisement

Mucopolysaccharidosis II (Hunter Syndrome)

  • Lorne A. Clarke

Mucopolysaccharidosis type II or Hunter syndrome is the only mucopolysaccharide storage disease to be inherited as an X-linked recessive disorder. Deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS; EC 3.1.6.13) is the primary defect in MPS I. As is seen with most X-linked potentially lethal conditions, allelic heterogeneity is significant and thus most families have individual or “private” mutations at the iduronate-2-sulfatase locus. In addition, unlike other LSDs, there is considerable heterogeneity in the molecular mechanisms underlying iduronate-2-sulfatase gene alteration in this condition. As such, this disorder, as with most of the MPSs, shows considerable clinical heterogeneity with the clinical phenotype spanning a spectrum of disease severity from early-onset childhood lethal disease to attenuated disease leading to a near normal life expectancy (Neufeld and Muenzer, 2001). In addition, patients with severe MPS II can have atypical symptomatology which likely relates to more complex genomic rearrangements underlying the disease pathogenesis. The incidence of MPS II appears to be variable in populations which have been studied, and range from 1 in 165,000 (Western Australia) to 1 in 34,000 (Israel) male live births; issues related to incomplete ascertainment in populations is noted in most studies (Lowry and Renwick, 1971; Schaap and Bach, 1980; Lowry et al., 1990; Poorthuis et al., 1999; Nelson, 1997; Meikle et al., 1999; Nelson et al., 2003). Therefore it is likely that MPS II is a panethnic disorder with an incidence in the order of 1 in 75,000 male live births. Increased incidence is expected to be seen in small populations where a founder effect would be anticipated.

Keywords

Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disease Hunter Syndrome Mucopolysaccharidosis Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Archer, I. M., Harper, P. S., and Wusterman, F.S., 1982, Multiple forms of iduronate-2-sulfatase in human tissues and body fluids. Biochem. Biophys. Acta. 708:134.PubMedGoogle Scholar
  2. Bergstrom, S. K, Quinn, J. J., Greenstein, R., and Ascensao, J., 1994, Long-term follow-up of a patient transplanted for Hunter’s disease type IIB: A case report and literature review. Bone Marrow Transplant. 14:653.PubMedGoogle Scholar
  3. Broadhead, D. M., Kirk, J. M., Burt, A. J., Gupta, V., Ellis, P. M., and Besley, G. T. N., 1986, Full expression of Hunter’s disease in a female with an X-chromosome deletion leading to non-random inactivation. Clin. Genet. 30:392.PubMedGoogle Scholar
  4. Clarke, J. T. R., Greer, W. L., Strasberg, P. M., Pearce, R. D., Skomorowski, M. A., and Ray, P. N., 1991, Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am. J. Hum. Genet. 49:289.PubMedGoogle Scholar
  5. Flomen, R. H., Green, E. P., Green, P. M., Bentley, D. R., and Giannelli, F., 1993, Determination of the organisation of coding sequences within the iduronate sulphate sulphatase (IDS) gene. Hum. Mol. Genet. 2:5.CrossRefPubMedGoogle Scholar
  6. Froissart, R., Moreira da Silva, I., Guffon, N., Bozon, D., and Maire, I., 2002, Mucopoly-saccharidosis type II-genotype/phenotype aspects. Acta. Paediatr. Suppl. 91:82.CrossRefPubMedGoogle Scholar
  7. Guffon, N., Froissart, R., Philippe, N., and Maire, I., 2001, Outcome of bone marrow transplantation in eight patients with Hunter disease. J. Inherit. Metab. Dis. 24(Suppl2):172Google Scholar
  8. Hunter, C., 1917, A rare disease in two brothers. Proc. R. Soc. Med. 10:104.PubMedGoogle Scholar
  9. Hurler, G., 1919, Über einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Zeitschrift für Kinderheilkunde. 24:220.CrossRefGoogle Scholar
  10. Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., Hoft, R., and Neufeld, E. F., 2001, Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344:182.CrossRefPubMedGoogle Scholar
  11. Lagerstedt, K., Carlberg, B. M., Karimi-Nejad, R., Kleijer, W. J., and Bondeson, M. L., 2000, Analysis of a 43.6 kb deletion in a patient with Hunter syndrome (MPSII): Identification of a fusion transcript including sequences from the gene W and the IDS gene. Hum. Mutat. 15:324.CrossRefPubMedGoogle Scholar
  12. Li, P., Thompson, J. N., Hug, G., Huffman, P., and Chuck, G., 1996, Biochemical and molecular analysis in a patient with the severe form of Hunter syndrome after bone marrow transplantation. Am. J. Med. Genet. 64:531.CrossRefPubMedGoogle Scholar
  13. Lowry, R. B., and Renwick, D. H., 1971, Relative frequency of the Hurler and Hunter syndromes. N. Engl. J. Med. 284:221.PubMedGoogle Scholar
  14. Lowry, R. B., Applegarth, D. A., Toone, J. R., MacDonald, E., and Thunem, N. Y., 1990, An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum. Genet. 85:389.CrossRefPubMedGoogle Scholar
  15. Lualdi, S., Regis, S., Di Rocco, M., Corsolini, F., Stroppiano, M., Antuzzi, D., and Filocamo, M., 2005, Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with Mucopolysaccharidosis type II revealed by a rapid PCR-based method. Hum. Mutat. 25:491.CrossRefPubMedGoogle Scholar
  16. McKinnis, E. J., Sulzbacher, S., Rutledge, J. C., Sanders, J., and Scott C. R., 1996, Bone marrow transplantation in Hunter syndrome. J. Pediatr. 129:145.CrossRefPubMedGoogle Scholar
  17. Meikle, P. J., Hopwood, J. J., Clague, A. E., and Carey, W. F., 1999, Prevalence of lysosomal storage disorders. JAMA 281:249.CrossRefPubMedGoogle Scholar
  18. Millat, G., Froissant, R., Maire, I., and Bozon, D., 1997, Characterization of iduronate sulfatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem. J. 326:243.PubMedGoogle Scholar
  19. Mossman, J., Blunt, S., Stephens, R., Jones, E. E., and Pembrey, M., 1983, Hunter’s disease in a girl: Association with X:5 chromosomal translocation disrupting the Hunter gene. Arch. Dis. Child. 58:911.CrossRefPubMedGoogle Scholar
  20. Muenzer, J., Lamsa, J. C., Garcia, A., Dacosta, J., Garcia, J., Treco, D. A., 2002, Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): A preliminary report. Acta. Paediatr. Suppl. 91:98.CrossRefPubMedGoogle Scholar
  21. Nelson, J., 1997, Incidence of the mucopolysaccharidoses in Northern Ireland. Hum. Gen. 101:355.CrossRefGoogle Scholar
  22. Nelson, J., Crowhurst, J., Carey, B., and Greed, L., 2003, Incidence of the mucopoly-saccharidoses in Western Australia. Am. J. Med. Gen. 123:310.CrossRefGoogle Scholar
  23. Neufeld, E. F., and Muenzer, J., 2001, The mucopolysaccharidoses, in: The Metabolic and Molecular Bases of Inherited Diseases, Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, R., Kinzler, K. W., 8th ed., McGraw-Hill, New York, pp. 3421-3452.Google Scholar
  24. Parkinson-Lawrence, E., Turner, C., Hopwood, J., and Brooks, D., 2005, Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochem. J. 386:395.CrossRefPubMedGoogle Scholar
  25. Poorthuis, B. J., Wevers, R. A., Kleijer, W. J., Groener, J. E., de Jong, J. G., van Weely, S., Niezen-Koning, K. E., and van Diggelen, O. P., 1999, The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 105:151.PubMedGoogle Scholar
  26. Rathmann, M., Bunge, S., Beck, M., Kresse, H., Tylki-Szymanska, A., and Gal, A., 1996, Mucopolysaccharidosis type II (Hunter syndrome): Mutation “hot spots” in the iduronate-2-sulfatase gene. Am. J. Hum. Genet. 59:1202.PubMedGoogle Scholar
  27. Rathmann, M., Bunge, S., Steglich, C., Schwinger, E., and Gal, A., 1995, Evidence for an iduronate-sulfatase pseudogene near the functional Hunter syndrome gene in Xq27.3-q28. Hum Genet. 95:34.CrossRefPubMedGoogle Scholar
  28. Sapadin, A. N., and Friedman, I. S., 1998, Extensive Mongolian spots associated with Hunter syndrome. J. Am. Acad. Derm. 39:1013.CrossRefPubMedGoogle Scholar
  29. Schaap, T., and Bach, G., 1980, Incidence of mucopolysaccharidoses in Israel: Is Hunter disease a ‘Jewish disease’? Hum. Genet. 56:221.CrossRefPubMedGoogle Scholar
  30. Sukegawa, K., Matsuzaki, T., Fukuda, S., Masuno, M., Fukao, T., Kokuryu, M., Iwata, S., Tomatsu, S., Orii, T., and Kondo, N., 1998, Brother/sister siblings affected with Hunter disease: Evidence for skewed X chromosome inactivation. Clin. Genet. 52:96.Google Scholar
  31. Timms, K. M., Bondeson, M. L., Ansari-LarI, M. A., Lagerstedt, K., Muzny, D. M., Dugan-Rocha, S. P., Nelson, D. L., Pettersson, U., and Gibbs, R. A., 1997, Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum. Mol. Genet. 6:479.CrossRefPubMedGoogle Scholar
  32. Timms, K. M., Lu, F., Shen, Y., Pierson, C. A., Muzny, D. M., Gu, Y., Nelson, D. L., Gibbs, R. A., 1995, 130 kb of DNA sequence reveals two new genes and a regional duplication distal to the human iduronate-2-sulfate sulfatase locus. Genome Res. 5:71.CrossRefPubMedGoogle Scholar
  33. Vafiadaki, E., Cooper, A., Heptinstall, L. E., Hatton, C. E., Thornley, M., and Wraith, J. E., 1998, Mutation analysis in 57 unrelated patients with MPS II (Hunter’s disease). Arch. Dis. Child. 79:237.CrossRefPubMedGoogle Scholar
  34. Vellodi, A., Young, E., Cooper, A., Lidchi, V., Winchester, B., and Wraith, J. E., 1999, Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22:638.CrossRefPubMedGoogle Scholar
  35. Wilson, P. J., Morris, C. P., Anson, D. S., Occhiodoro, T., Bielicki, J., Clements, P. R., and Hopwood, J. J., 1990, Hunter syndrome: Isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc. Nat. Acad. Sci. 87:8531.CrossRefPubMedGoogle Scholar
  36. Wilson, P. J., Suthers, G. K., Callen, D. F., Baker, E., Nelson, P. V., Cooper, A., Wraith, J. E., Sutherland, G. R., Morris, C. P., and Hopwood, J. J., 1991, Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum. Genet. 86:505.CrossRefPubMedGoogle Scholar
  37. Winchester, B., Young, E., Geddes, S., Genet, S., Hurst, J., Middleton-Price, H., Williams, N., Webb, M., Habel, A., and Malcolm, S., 1992, Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: A consequence of twinning. Am. J. Med. Genet. 44:834.CrossRefPubMedGoogle Scholar
  38. Wraith, J. E., Clarke, L. A., Beck, M., Kolodny, E. H., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Swiedler, S. J., Kakkis, E. D., Braakman, T., Chadbourne, E., Walton-Bowen, K., and Cox, G. F., 2004, Enzyme replacement therapy for Mucopolysaccharidosis I: A randomized, double-blind, placebo-controlled, multinational study of recombinant human a-L-iduronidase (Laronidase). J. Pediatr. 144:581.CrossRefPubMedGoogle Scholar
  39. Wraith, J. E., Cooper, A., Thornley, M., Wilson, P. J., Nelson, P. V., Morris, C. P., and Hopwood, J. J., 1991, The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II-Hunter syndrome). Hum. Genet. 87:205.CrossRefPubMedGoogle Scholar
  40. Young, I. D., and Harper, P. S., 1979, Long-term complications in Hunter’s syndrome. Clin. Genet. 16:125.PubMedCrossRefGoogle Scholar
  41. Young, I. D., and Harper, P. S., 1982, Mild form of Hunter’s syndrome: Clinical delineation based on 31 cases. Arch. Dis. Child. 57:828.CrossRefPubMedGoogle Scholar
  42. Young, I. D., and Harper, P. S., 1983, The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 25:481.PubMedGoogle Scholar
  43. Young, I. D., Harper, P. S., Archer, I. M., and Newcombe, R. G., 1982b, A clinical and genetic study of Hunter’s syndrome. 1. Heterogeneity. J. Med. Gen. 19:401.CrossRefGoogle Scholar
  44. Young, I. D., Harper, P. S., Newcombe, R. G., and Archer, I. M., 1982a, A clinical and genetic study of Hunter’s syndrome. 2. Differences between the mild and severe forms. J. Med. Gen. 19:408.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Lorne A. Clarke
    • 1
  1. 1.Department of Medical GeneticsUniversity of British Columbia, Child and Family Research InstituteVancouverCanada

Personalised recommendations